When isorhamnetin interacts with the cancer cell, it downregulates key molecular markers playing a key role in tumor progression, including MMP-2 and MMP-9 (matrix metalloproteinases accountable for degrading the basement membrane) [96]. Here, MMP9 is linked to neoplasm.